<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852021000200002</article-id>
<article-id pub-id-type="doi">10.48193/revistamexicanadeurologa.v81i2.578</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Asociación entre síndrome metabólico y niveles de antígeno prostático específico en varones que acudieron a control prostático al servicio de urología del Hospital Belén de Trujillo, Perú]]></article-title>
<article-title xml:lang="en"><![CDATA[Association between metabolic syndrome and levels of specific prostate antigen in men who attended prostate control at the urology service of the Hospital Belén de Trujillo, Peru]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cerna-Jamanca]]></surname>
<given-names><![CDATA[Judith]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gamboa-Vicente]]></surname>
<given-names><![CDATA[Willy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Privada Antenor Orrego Facultad de Medicina Humana ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Belén de Trujillo  ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Perú</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2021</year>
</pub-date>
<volume>81</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852021000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852021000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852021000200002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Determinar si existe asociación entre el síndrome metabólico (MetS) y los niveles de antígeno prostático específico (PSA) en varones que acudieron a control prostático al servicio de urología del Hospital Belén de Trujillo.  Material y Métodos: Se realizó un estudio observacional, analítico y transversal, en el cual se incluyeron 357 varones entre 50-70 años, que acudieron a control prostático al Servicio de Urología del Hospital Belén de Trujillo durante el periodo marzo-julio del año 2019, que cumplieron los criterios de selección. Según los criterios de la National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) los pacientes fueron dicotómizados por la presencia o ausencia de MetS y se calculó la media de los niveles de PSA en cada grupo. Posteriormente se realizó un análisis de regresión lineal para evaluar el efecto de la edad, IMC, volumen prostático, volumen plasmático y puntaje de síntomas de tracto urinario inferior sobre los niveles de PSA.  Resultados: En el grupo de varones con MetS, la media de los niveles de PSA fue ligeramente menor que en los varones sin MetS (1.54 ± 2.39 vs 1.85 ± 3.0); obteniéndose una diferencia de 0.31 ng/ml; sin embargo, esta asociación no fue estadísticamente significativa (p= 0.103). Por otro lado, los niveles de PSA se vieron influenciados por el volumen de plasma sanguíneo (p=0.007) e IMC (p=0.017).  Conclusiones: Los resultados obtenidos en esta población reflejan que la presencia de MetS tuvo una asociación no significativa sobre los niveles de PSA; sin embargo, estos hallazgos pueden estar influenciados por un efecto antagónico entre cada uno de los componentes de MetS.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To determine if there is an association between the metabolic syndrome (MetS) and the levels of prostate specific antigen (PSA) in men who attended prostate control at the urology service of the Belén de Trujillo Hospital.  Material and Methods: An observational, analytical and cross-sectional study was carried out, in which 357 men between 50-70 years were included, who went to a prostate control at the Urology Service of the Belén de Trujillo Hospital during the period March - July of the year 2019, which met the selection criteria. According to the criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII), patients were dichotomized by the presence or absence of MetS and the means of PSA levels in each group were calculated. Subsequently, a linear regression analysis was performed to assess the effect of age, BMI, prostate volume, blood plasma volume and lower urinary tract symptoms score on PSA levels.  Results: In the group of men with MetS, the mean PSA levels were slightly lower than men without MetS (1.54 ± 2.39 vs. 1.85 ± 3.0); obtaining a difference of 0.31 ng/ml; however, this association was not statistically significant (p = 0.103). On the other hand, PSA levels were influenced by blood plasma volume (p = 0.007) and BMI (p = 0.017).  Conclusions: The results obtained in this population affected that the presence of MetS had a non-significant association on PSA levels; however, these findings may be reflected by an antagonistic effect between each of the components of MetS.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Metabolic syndrome]]></kwd>
<kwd lng="en"><![CDATA[specific prostate antigen]]></kwd>
<kwd lng="en"><![CDATA[insulin resistance]]></kwd>
<kwd lng="es"><![CDATA[Síndrome Metabólico]]></kwd>
<kwd lng="es"><![CDATA[Antígeno Prostático Específico]]></kwd>
<kwd lng="es"><![CDATA[Resistencia a la insulina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[Y-J]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[Y-J]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[J-E]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[Y-S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S-C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[W-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between metabolic syndrome and prostate-specific antigen levels]]></article-title>
<source><![CDATA[Int J Urol]]></source>
<year>2008</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>905-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prcic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Begic]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hiros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Usefulness of Total PSA Value in Prostate Diseases Diagnosis]]></article-title>
<source><![CDATA[Acta Inform Med]]></source>
<year>2016</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>156-61</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Albertsen]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Babaian]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Gann]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate specific antigen best practice statement: 2009 update]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2013</year>
<volume>189</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S2-11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brenes Bermúdez]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso del antígeno prostático específico en atención primaria]]></article-title>
<source><![CDATA[SEMERGEN - Med Fam]]></source>
<year>2017</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>173-4</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lizarzaburu Robles]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome metabólico: concepto y aplicación práctica]]></article-title>
<source><![CDATA[An Fac Med]]></source>
<year>2014</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>315</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villalobos Sánchez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Millán García]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Narankievickz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome metabólico]]></article-title>
<source><![CDATA[Med - Programa Form Médica Contin Acreditado]]></source>
<year>2017</year>
<volume>12</volume>
<numero>42</numero>
<issue>42</issue>
<page-range>2485-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvajal Carvajal]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome Metabólico: Definiciones, epidemiología, etiología, componentes y tratamiento]]></article-title>
<source><![CDATA[Medicina Legal de Costa Rica]]></source>
<year>2017</year>
<page-range>175-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab>
<article-title xml:lang=""><![CDATA[Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2486-97</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fridrich]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Bonneau]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrozo]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Novau]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación entre obesidad e insulino resistencia con el antígeno prostático específico]]></article-title>
<source><![CDATA[Rev.Cienc. Tecnol]]></source>
<year>2012</year>
<page-range>44-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio-García]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes-García]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios-Saucedo]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparación de los valores de antígeno prostático específico en pacientes con y sin obesidad abdominal del servicio de urología de una unidad médica de tercer nivel de atención]]></article-title>
<source><![CDATA[Rev Mex Urol]]></source>
<year>2015</year>
<volume>75</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>64-71</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2017</year>
<volume>120</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>482-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[C-S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association of metabolic syndrome and its components with serum prostate-specific antigen levels in a Korean-screened population]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2010</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>371-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salih]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Abdulla]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Shaam&#8221;a]]></surname>
<given-names><![CDATA[QA-S]]></given-names>
</name>
<name>
<surname><![CDATA[Saeed]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Hussein]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of metabolic syndrome on prostate specific antigen level, prostate volume and international prostate symptom scores in patients with benign prostatic hyperplasia]]></article-title>
<source><![CDATA[Zanco J Med Sci]]></source>
<year>2016</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1385-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cyrus]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kabir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goodarzi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Talaei]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moradi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rafiee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia]]></article-title>
<source><![CDATA[Korean J Urol]]></source>
<year>2014</year>
<volume>55</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>814-20</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gidron]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fabre]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Grosman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nolazco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mesch]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mazza]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Life events, cortisol and levels of prostate specific antigen: a story of synergism]]></article-title>
<source><![CDATA[Psychoneuroendocrinology]]></source>
<year>2011</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>874-80</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montorsi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Briganti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome as a marker for prostate cancer: still a work in progress]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2015</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-2</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhindi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fleshner]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reply from Authors re: Andrea Gallina, Alessandro Nini, Francesco Montorsi, Alberto Briganti. Metabolic Syndrome as a Marker for Prostate Cancer: Still a Work in Progress. Eur Urol 2015;67:71-2]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2015</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>72-3</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Najar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Faisal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khesal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ansari]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome and its association with benign prostatic hyperplasia with special reference to unani system of medicine: A review]]></article-title>
<source><![CDATA[J Biol Sci Opin]]></source>
<year>2017</year>
<volume>5</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Heo]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paick]]></surname>
<given-names><![CDATA[J-S]]></given-names>
</name>
<name>
<surname><![CDATA[Son]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific antigen lowering effect of metabolic syndrome is influenced by prostate volume]]></article-title>
<source><![CDATA[Int J Urol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>299-304</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[T-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[D-H]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[T-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[H-C]]></given-names>
</name>
<name>
<surname><![CDATA[An]]></surname>
<given-names><![CDATA[Y-I]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[S-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of Metabolic Factors with Prostate Volume and Prostate-Specific Antigen]]></article-title>
<source><![CDATA[Korean Journal of Family Practice]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-46</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Y-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[D-Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2016</year>
<volume>95</volume>
<numero>19</numero>
<issue>19</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Daneshgari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[MacLennan]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links]]></article-title>
<source><![CDATA[Prostate Cancer Prostatic Dis]]></source>
<year>2016</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-13</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J-R]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[J-M]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[K-Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men]]></article-title>
<source><![CDATA[Asian J Androl]]></source>
<year>2015</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>826-30</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sáenz Medina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carballido Rodríguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos fisiopatológicos implicados en la patología urologica asociada al síndrome metabólico. Revisión bibliográfica]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2016</year>
<volume>40</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>279-87</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carreño]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Arciniegas]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos Ulloa]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Mayans]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Cano]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asociación entre obesidad y diagnóstico de cáncer de próstata en adultos mayores: análisis secundario de la encuesta SABE]]></article-title>
<source><![CDATA[Rev Urol Colomb Colomb Urol J]]></source>
<year>2019</year>
<volume>28</volume>
<numero>03</numero>
<issue>03</issue>
<page-range>240-5</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muazu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bako]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity Indices and Serum Total Prostate Specific Antigen among Hausa Ethnic Group of Northern Nigeria; A Community Survey]]></article-title>
<source><![CDATA[American Journal of Medicine and Medical Sciences]]></source>
<year>2018</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>61-5</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGrowder]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer and metabolic syndrome: is there a link?]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2012</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esposito]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chiodini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Capuano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bellastella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maiorino]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Parretta]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis]]></article-title>
<source><![CDATA[J Endocrinol Invest]]></source>
<year>2013</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>132-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Hemelrijck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garmo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Holmberg]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Walldius]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jungner]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hammar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2011</year>
<volume>117</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2086-95</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xiong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence]]></article-title>
<source><![CDATA[J Exp Clin Cancer Res]]></source>
<year>2013</year>
<volume>32</volume>
<page-range>9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
